|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | C07D 471/04 | |
| A61K 31/55 | |||
| A61P 3/04 |
| (11) | Patento numeris | 3402796 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 17700748.1 |
| Europos patento paraiškos padavimo data | 2017-01-09 | |
| (97) | Europos patento paraiškos paskelbimo data | 2018-11-21 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2020-11-18 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/IB2017/050094 |
| Data | 2017-01-09 |
| (87) | Numeris | WO 2017/122116 |
| Data | 2017-07-20 |
| (30) | Numeris | Data | Šalis |
| 201662279037 P | 2016-01-15 | US |
| (72) |
CHAPPIE, Thomas Allen, US
HENDERSON, Jaclyn Louise, US
YOUNG, Joseph Michael, US
WAGER, Travis T., US
KORMOS, Bethany Lyn, US
PATEL, Nandini Chaturbhai, US
SCIABOLA, Simone, US
TUTTLE, Jamison Bryce, US
VERHOEST, Patrick Robert, US
TUCKER, Joseph Walter, US
|
| (73) |
Pfizer Inc.,
235 East 42nd Street, New York, NY 10017,
US
|
| (54) | 6,7,8,9-TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINE DOPAMINE D3 LIGANDS |
| 6,7,8,9-TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINE DOPAMINE D3 LIGANDS |